• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 4:30:40 PM ET
    $KDMN
    Major Pharmaceuticals
    Health Care
    Get the next $KDMN alert in real time by email
    SC 13G/A 1 ea135463-13ga4vivo8_kadmon.htm AMENDMENT NO. 4 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 4)*

     

    Kadmon Holdings, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.001 par value

     

    (Title of Class of Securities)

     

    48283N106

     

    (CUSIP Number)

     

    December 31, 2020

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 48283N106
    1 NAMES OF REPORTING PERSONS  
    Vivo Capital VIII, LLC  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
    (a) ☒
    (b) ☐
    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    2,867,777 (1)
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER
    2,867,777 (1)
    8 SHARED DISPOSITIVE POWER
    0
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    2,867,777 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
    ☐
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    1.7% (2)
    12 TYPE OF REPORTING PERSON (See Instructions)
    OO
             

    (1)The number includes (i) 1,534,445 shares of common stock, par value $0.001 per share (“Common Stock”) and (ii) 1,333,332 shares of Common Stock issuable upon exercise of 1,333,332 warrants. The exercise of the 1,333,332 warrants is subject to a beneficial ownership limitation of 9.99% of the Issuer’s outstanding shares of Common Stock. The securities are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P.
    (2)Based on (i) 171,512,945 shares of Common Stock of the Issuer outstanding as of November 2, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2020, plus (ii) 1,333,332 shares of Common Stock issuable upon exercise of 1,333,332 warrants.

     

    2

     

     

    CUSIP No. 48283N106
    1 NAMES OF REPORTING PERSONS  
    Vivo Opportunity, LLC  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
    (a) ☒
    (b) ☐
    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    4,283,014 (1)
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER
    4,283,014 (1)
    8 SHARED DISPOSITIVE POWER
    0
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    4,283,014 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
    ☐
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    2.5% (2)
    12 TYPE OF REPORTING PERSON (See Instructions)
    OO
             

    (1)The shares of Common Stock are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P.
    (2)Based on (i) 171,512,945 shares of Common Stock of the Issuer outstanding as of November 2, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2020, plus (ii) 1,333,332 shares of Common Stock issuable upon exercise of 1,333,332 warrants, which are held of record by Vivo Capital Fund IX, L.P.

     

    3

     

     

    Item 1. (a)Name of Issuer:

     

    Kadmon Holdings, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    450 East 29th Street

    New York, New York 10016

     

    Item 2. (a)Name of Person Filing:

     

    This 13G Amendment No. 4 is filed jointly by Vivo Capital VIII, LLC and Vivo Opportunity, LLC.

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    192 Lytton Avenue, Palo Alto, CA 94301

     

    (c)Citizenship:

     

    Vivo Capital VIII, LLC is a Delaware limited liability company.

     

    Vivo Opportunity, LLC is a Delaware limited liability company.

     

    (d)Title of Class of Securities:

     

    Common Stock

     

    (e)CUSIP Number:

     

    48283N106

     

    Item 3.If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act.
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act.
           
      (c) ☐  Insurance company as defined in Section 3(a)(19) of the Act.
           
      (d) ☐  Investment company registered under Section 8 of the Investment Company Act of 1940.
           
      (e) ☐  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) ☐  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) ☐  A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);
           
      (h) ☐  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           
      (i) ☐  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
      (j) ☐  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ☐  Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

     

    Not Applicable.

     

    4

     

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    (1) Vivo Capital VIII, LLC

     

    The 2,867,777 shares of Common Stock and warrants exercisable into 1,333,332 shares of Common Stock are held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P.

     

    Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. The voting members of Vivo Capital VIII, LLC are Frank Kung, Edgar Engleman and Shan Fu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

     

    (2) Vivo Opportunity, LLC

     

    The 4,283,014 shares of Common Stock are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

     

    (b)Percent of class:

     

    Vivo Capital VIII, LLC: 1.7%

     

    Vivo Opportunity, LLC: 2.5%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    Vivo Capital VIII, LLC: 2,867,777 shares

     

    Vivo Opportunity, LLC: 4,283,014 shares

     

    (ii)Shared power to vote or to direct the vote: 0

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    Vivo Capital VIII, LLC: 2,867,777 shares

     

    Vivo Opportunity, LLC: 4,283,014 shares

     

    (iv)Shared power to dispose of or to direct the disposition of: 0

     

    5

     

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

     

    6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Vivo Capital VIII, LLC
       
      February 12, 2021
      (Date)
       
      /s/ Frank Kung
      (Signature)
       
      Managing Member
      (Title)
       
      Vivo Opportunity, LLC
       
      February 12, 2021
      (Date)
       
      /s/ Gaurav Aggarwal
      (Signature)
       
      Managing Member
      (Title)

     

     

    7

     

     

    Get the next $KDMN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KDMN

    DatePrice TargetRatingAnalyst
    9/14/2021$13.00 → $9.50Buy → Neutral
    Mizuho
    9/9/2021$10.00 → $9.50Buy → Hold
    Jefferies
    7/19/2021$8.00 → $9.00Outperform
    Oppenheimer
    More analyst ratings

    $KDMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Flowers Cynthia Louise gifted 20,150 shares and returned $103,075 worth of shares to the company (10,850 units at $9.50), closing all direct ownership in the company

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:41:38 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Cohen David E

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:37:34 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Ryan John L

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:41:04 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Kadmon Holdings, Inc.

      SC 13D - Kadmon Holdings, Inc. (0001557142) (Subject)

      9/17/21 8:24:15 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Kadmon Holdings, Inc. (Amendment)

      SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)

      5/28/21 5:04:26 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)

      2/17/21 3:12:07 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kadmon Holdings downgraded by Mizuho with a new price target

      Mizuho downgraded Kadmon Holdings from Buy to Neutral and set a new price target of $9.50 from $13.00 previously

      9/14/21 7:13:20 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Kadmon Holdings downgraded by Jefferies with a new price target

      Jefferies downgraded Kadmon Holdings from Buy to Hold and set a new price target of $9.50 from $10.00 previously

      9/9/21 5:30:28 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Oppenheimer reiterated coverage on Kadmon Holdings with a new price target

      Oppenheimer reiterated coverage of Kadmon Holdings with a rating of Outperform and set a new price target of $9.00 from $8.00 previously

      7/19/21 7:45:32 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

      Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton's expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programsDevelopment to focus on serious disorders that have few-to-no therapeutic options, including cerebral cavernous malformations and conditions presenting with seizuresOvid to invest $10 million in preferred equity in Graviton and will fund development programsTransaction has no milestone payments and Graviton is eligible for tiered double-digit royalties on commercial sales NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -

      5/1/23 6:00:00 AM ET
      $MGTX
      $OVID
      $KDMN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Major Pharmaceuticals
    • Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

      - REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States -- Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million -- Sanofi acquisition of Kadmon expected to close 4Q 2021 -NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021."The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following

      11/4/21 8:00:00 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Leadership Updates

    Live Leadership Updates

    See more
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Kadmon Announces Appointment of Dr. Simon Cooper as Chief Medical Officer

      NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper, MBBS, as Senior Vice President, Chief Medical Officer, effective March 1, 2021. In this role, Dr. Cooper will oversee the Company's medical and clinical activities relating to the potential regulatory approval of belumosudil for chronic graft-versus-host disease and lead the Company's clinical team to advance the development of additional product candidates. Dr. Cooper succeeds John Ryan, M.D., Ph.D., who will remain with the Company and transition to the role of Executive Medical Director, Clinical and Regulatory Development, where he will continue to advise on c

      3/1/21 8:00:00 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Financials

    Live finance-specific insights

    See more
    • Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

      - REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States -- Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million -- Sanofi acquisition of Kadmon expected to close 4Q 2021 -NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021."The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following

      11/4/21 8:00:00 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results

      NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021."The recent U.S. FDA approval of REZUROCK marked a transformative event for Kadmon and for patients living with cGVHD. REZUROCK represents a paradigm shift in the cGVHD treatment landscape by uniquely addressing both the immune and fibrotic components of the disease," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We look forward to bringing this meaningful new therapy to patients in the U.S. by the end of this month."Dr. Waksal added, "Our momentum continues as we advance our portfolio of p

      8/5/21 4:05:00 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Kadmon Provides Business Update and Reports First Quarter 2021 Financial Results

      NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021."We continue to ramp up commercial launch preparation activities for belumosudil in anticipation of the PDUFA goal date of August 30, 2021. Labeling discussions with the FDA are progressing and we believe that belumosudil, if approved, will serve a critical, unmet need for patients with cGVHD," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "In addition, we are exploring the therapeutic potential of belumosudil in systemic sclerosis, a disease with similar manifestations to cGVHD. We continue to

      5/6/21 4:01:00 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    SEC Filings

    See more
    • SEC Form 15-12B filed by Kadmon Holdings, Inc.

      15-12B - Kadmon Holdings, Inc. (0001557142) (Filer)

      11/19/21 4:01:10 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Kadmon Holdings, Inc.

      EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)

      11/16/21 12:15:18 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Kadmon Holdings, Inc.

      EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)

      11/16/21 12:15:09 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care